Stockscreener 앱 받기
4.945
3.57%
-0.095
전일 마감가:
$5.04
열려 있는:
$4.92
하루 거래량:
26,542
Relative Volume:
0.40
시가총액:
$50.48M
수익:
$1.93M
순이익/손실:
$-7.96M
주가수익비율:
-0.0014
EPS:
-3530.8178
순현금흐름:
$-36.78M
1주 성능:
+2.75%
1개월 성능:
-16.21%
6개월 성능:
-63.81%
1년 성능:
-66.16%
1일 변동 폭
$4.68
$5.11
1주일 범위
$4.56
$5.47
52주 변동 폭
$4.15
$16.00
아발로 테라퓨틱스 Stock (AVTX) Company Profile
명칭
Avalo Therapeutics Inc
전화
410-522-8707
주소
540 GAITHER ROAD, ROCKVILLE
AVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
4.945 | 50.48M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.22 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.86 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.48 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.64 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
아발로 테라퓨틱스 Stock (AVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-25 | 개시 | Jefferies | Buy |
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-28 | 개시 | Piper Sandler | Overweight |
| 2025-02-21 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-10-24 | 개시 | H.C. Wainwright | Neutral |
| 2024-04-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-09-24 | 개시 | RBC Capital Mkts | Outperform |
모두보기
아발로 테라퓨틱스 주식(AVTX)의 최신 뉴스
Geode Capital Management LLC Increases Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference - The Manila Times
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 20.3% in March - Defense World
60,000 Shares in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Purchased by Bank of Montreal Can - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $33.00 Average PT from Brokerages - Defense World
Avalo Therapeutics (AVTX) Sees New Options Listings for April | AVTX Stock News - GuruFocus
Seven new option listings and one option delisting on April 16th - TipRanks
Avalo Therapeutics Reports 2024 Financial Results - TipRanks
Advanced Cancer Pain Management Therapeutics Market Size in 7MM - openPR.com
(AVTX) On The My Stocks Page - news.stocktradersdaily.com
AVTX stock touches 52-week low at $5.98 amid market challenges - Investing.com Australia
AVTX stock touches 52-week low at $5.98 amid market challenges By Investing.com - Investing.com South Africa
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Stifel Nicolaus - MarketBeat
Avalo Therapeutics (AVTX) to Release Earnings on Friday - Defense World
Analysts Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00 - Defense World
Avalo Therapeutics names new Chairman amid growth phase By Investing.com - Investing.com South Africa
Avalo Therapeutics Names Michael Heffernan as Board Chairman - MarketScreener
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board - GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board - MarketScreener
Avalo Therapeutics names new Chairman amid growth phase - Investing.com
DynaCERT And Avalo Therapeutics Poised For Growth - Evrim Ağacı
Avalo Therapeutics Appoints Michael Heffernan as Chairman - TipRanks
Stifel initiates Avalo Therapeutics stock with a Buy rating By Investing.com - Investing.com Australia
Jefferies Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside - Benzinga
Jefferies starts Avalo stock with Buy, sets $23 price target By Investing.com - Investing.com Australia
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Stifel Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq
Stifel Initiates Avalo Therapeutics at Buy With $36 Price Target - MarketScreener
How the (AVTX) price action is used to our Advantage - news.stocktradersdaily.com
Jefferies starts Avalo stock with Buy, sets $23 price target - Investing.com
Stifel initiates Avalo Therapeutics stock with a Buy rating - Investing.com India
Oppenheimer maintains Avalo stock Outperform with $35 target By Investing.com - Investing.com Canada
Oppenheimer maintains Avalo stock Outperform with $35 target - Investing.com
Equities Analysts Set Expectations for AVTX Q1 Earnings - Defense World
Wedbush Research Analysts Lift Earnings Estimates for AVTX - Defense World
Wedbush Forecasts Increased Earnings for Avalo Therapeutics - The AM Reporter
HC Wainwright Reiterates Neutral Rating for Avalo Therapeutics (NASDAQ:AVTX) - Defense World
Q1 EPS Estimates for Avalo Therapeutics Boosted by Wedbush - Defense World
Avalo Reports 2024 Financial Results and Recent Business Updates - GlobeNewswire
Avalo Therapeutics Reports Business Updates and Financial Results for 2024, Highlights Phase 2 LOTUS Trial Progress for AVTX-009 in Hidradenitis Suppurativa - Nasdaq
Avalo Therapeutics, Inc. SEC 10-K Report - TradingView
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday - Defense World
Avalo Therapeutics (AVTX) Receives a Hold from H.C. Wainwright - The Globe and Mail
AVTX’s 52-Week Rollercoaster: From $4.35 to $34.46 – What’s Next for Investors? - The InvestChronicle
PSTV Rallies, TOVX Gears Up For VIRAGE Trial Data, Will AVTX's LOTUS Bloom? - RTTNews
(AVTX) Investment Analysis - Stock Traders Daily
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Piper Sandler - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight Recommendation - Nasdaq
아발로 테라퓨틱스 (AVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):